InMed Pharmaceuticals (INM)
Market Price (3/30/2026): $0.6581 | Market Cap: $2.6 MilSector: Health Care | Industry: Pharmaceuticals
InMed Pharmaceuticals (INM)
Market Price (3/30/2026): $0.6581Market Cap: $2.6 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -246% | Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -160% | Penny stockMkt Price is 0.7 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -174% | |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -6.7%, Rev Chg QQuarterly Revenue Change % is -26% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -165%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -165% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -297% | ||
| High stock price volatilityVol 12M is 114% | ||
| Key risksINM key risks include [1] a limited cash runway projected to fund operations only into late 2026 and [2] adverse U.S. Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -246% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -160% |
| Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -174% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -6.7%, Rev Chg QQuarterly Revenue Change % is -26% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -165%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -165% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -297% |
| High stock price volatilityVol 12M is 114% |
| Key risksINM key risks include [1] a limited cash runway projected to fund operations only into late 2026 and [2] adverse U.S. Show more. |
Qualitative Assessment
AI Analysis | Feedback
InMed Pharmaceuticals (INM) stock has lost about 50% since 11/30/2025 because of the following key factors:
1. Continued Cash Burn and Financial Losses.
InMed Pharmaceuticals reported a decrease in its cash, cash equivalents, and short-term investments from $9.3 million as of September 30, 2025, to $7.0 million by December 31, 2025. The company also anticipates that research and development expenses will "increase substantially" throughout the remainder of fiscal year 2026 as it advances its preclinical work and IND-enabling studies for the INM-901 program, indicating an ongoing significant cash burn.
2. Prolonged Clinical Development Timelines.
The timeline for advancing InMed's lead drug candidates indicates a lengthy development period before potential commercialization. The company is planning a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for its Alzheimer's disease candidate, INM-901, in Q3 2026, with the initiation of a Phase 1 clinical trial targeted for 2027. Similarly, a pre-IND meeting for INM-089, targeting dry age-related macular degeneration, is scheduled for Q4 2026. These extended timelines contribute to investor uncertainty in early-stage pharmaceutical development.
Show more
1. Continued Cash Burn and Financial Losses.
InMed Pharmaceuticals reported a decrease in its cash, cash equivalents, and short-term investments from $9.3 million as of September 30, 2025, to $7.0 million by December 31, 2025. The company also anticipates that research and development expenses will "increase substantially" throughout the remainder of fiscal year 2026 as it advances its preclinical work and IND-enabling studies for the INM-901 program, indicating an ongoing significant cash burn.
2. Prolonged Clinical Development Timelines.
The timeline for advancing InMed's lead drug candidates indicates a lengthy development period before potential commercialization. The company is planning a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for its Alzheimer's disease candidate, INM-901, in Q3 2026, with the initiation of a Phase 1 clinical trial targeted for 2027. Similarly, a pre-IND meeting for INM-089, targeting dry age-related macular degeneration, is scheduled for Q4 2026. These extended timelines contribute to investor uncertainty in early-stage pharmaceutical development.
Show more
Stock Movement Drivers
Fundamental Drivers
The -50.7% change in INM stock from 11/30/2025 to 3/29/2026 was primarily driven by a -47.5% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.33 | 0.66 | -50.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | -6.1% |
| P/S Multiple | 1.1 | 0.6 | -47.5% |
| Shares Outstanding (Mil) | 4 | 4 | 0.0% |
| Cumulative Contribution | -50.7% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| INM | -50.7% | |
| Market (SPY) | -5.3% | 24.6% |
| Sector (XLV) | -8.7% | 3.3% |
Fundamental Drivers
The -70.5% change in INM stock from 8/31/2025 to 3/29/2026 was primarily driven by a -72.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.22 | 0.66 | -70.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | -8.4% |
| P/S Multiple | 0.5 | 0.6 | 16.4% |
| Shares Outstanding (Mil) | 1 | 4 | -72.3% |
| Cumulative Contribution | -70.5% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| INM | -70.5% | |
| Market (SPY) | 0.6% | 26.2% |
| Sector (XLV) | 5.2% | 14.1% |
Fundamental Drivers
The -77.7% change in INM stock from 2/28/2025 to 3/29/2026 was primarily driven by a -82.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.94 | 0.66 | -77.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | -6.7% |
| P/S Multiple | 0.4 | 0.6 | 33.9% |
| Shares Outstanding (Mil) | 1 | 4 | -82.1% |
| Cumulative Contribution | -77.7% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| INM | -77.7% | |
| Market (SPY) | 9.8% | 19.0% |
| Sector (XLV) | -2.1% | 8.3% |
Fundamental Drivers
The -97.5% change in INM stock from 2/28/2023 to 3/29/2026 was primarily driven by a -97.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.60 | 0.66 | -97.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 5 | 179.1% |
| P/S Multiple | 1.9 | 0.6 | -69.6% |
| Shares Outstanding (Mil) | 0 | 4 | -97.1% |
| Cumulative Contribution | -97.5% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| INM | -97.5% | |
| Market (SPY) | 69.4% | 10.3% |
| Sector (XLV) | 18.4% | 6.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| INM Return | -60% | -94% | -79% | -43% | -78% | -36% | -100% |
| Peers Return | -39% | -40% | 7% | 28% | 5% | 3% | -45% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| INM Win Rate | 42% | 17% | 25% | 42% | 17% | 33% | |
| Peers Win Rate | 33% | 37% | 44% | 50% | 46% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| INM Max Drawdown | -60% | -96% | -84% | -71% | -78% | -36% | |
| Peers Max Drawdown | -40% | -47% | -27% | -9% | -30% | -9% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JAZZ, CRON, CRBP, IGC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | INM | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.8% | -25.4% |
| % Gain to Breakeven | 40442.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to JAZZ, CRON, CRBP, IGC
In The Past
InMed Pharmaceuticals's stock fell -99.8% during the 2022 Inflation Shock from a high on 2/11/2021. A -99.8% loss requires a 40442.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About InMed Pharmaceuticals (INM)
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
AI Analysis | Feedback
Here are a few brief analogies for InMed Pharmaceuticals:
It's like an early-stage GW Pharmaceuticals (a company known for its cannabis-derived prescription drugs) focused on developing new cannabinoid treatments for conditions such as rare skin diseases and glaucoma.
Think of it as a clinical-stage biotech company, much like Moderna or BioNTech use a specific technology platform (mRNA) for drug development, but InMed's platform focuses on creating new medicines from cannabinoids.
AI Analysis | Feedback
- INM-755: A cannabinol topical cream in clinical trials for the treatment of epidermolysis bullosa.
- INM-088: A cannabinoid-based therapy in preclinical studies for the treatment of glaucoma.
- INM-405: A cannabinoid-based therapy in preclinical studies for the treatment of pain.
- IntegraSyn: An integrated biosynthesis-based manufacturing approach for synthesizing pharmaceutical-grade cannabinoids.
AI Analysis | Feedback
InMed Pharmaceuticals Inc. (INM) is a clinical-stage pharmaceutical company focused on the research and development of cannabinoid-based therapies. According to the provided description, its lead product, INM-755, is in Phase I clinical trials, and other drug candidates (INM-088, INM-405) are in preclinical studies. The company is actively engaged in R&D, preclinical toxicology studies, and developing manufacturing approaches.
As a clinical-stage company, InMed Pharmaceuticals Inc. does not currently have any commercialized products on the market. Therefore, it does not have major customers, either other companies or individual consumers, from the sale of its therapies at this time. Its primary activities revolve around advancing its drug candidates through the various stages of clinical development and regulatory approval.
AI Analysis | Feedback
- BayMedica Inc.
AI Analysis | Feedback
Eric A. Adams, MIBSChief Executive Officer & President
Mr. Adams was appointed Chief Executive Officer, President, and Director of InMed Pharmaceuticals in June 2016. He is a seasoned biopharmaceutical executive with over 30 years of experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing, and corporate governance. He previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, he held senior positions in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG. He is well-respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies.
Netta Jagpal, CPA, CAChief Financial Officer and Corporate Secretary
Ms. Jagpal was appointed Chief Financial Officer and Corporate Secretary, effective February 20, 2024. She brings over 20 years of experience in financial leadership roles, primarily within the biotech industry. Before joining InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she led a finance team through the initial public offering process. She also spent 11 years at Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, in various financial capacities, including Senior Director, Finance & Corporate Controller. Her prior experience also includes roles at Angiotech Pharmaceuticals, Inc. and Ernst & Young. She is a Chartered Professional Accountant.
Michael Woudenberg, P.Eng.Chief Operating Officer
Mr. Woudenberg joined InMed in 2018 and has over 20 years of experience in engineering, scale-up, and GMP manufacturing of active pharmaceutical ingredients (APIs) and drug products. His experience includes process and formulation development from lab/pre-clinical products through various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Prior to InMed, he held various positions within 3M, Cardiome Pharma, Arbutus Biopharma, and most recently served as the Managing Director of Phyton Biotech, LLC.
Alexandra Mancini, M.Sc.Senior Vice President, Clinical & Regulatory Affairs
Ms. Mancini was appointed Senior Vice President, Clinical and Regulatory Affairs in October 2016. She has over 30 years of global biopharmaceutical research and development experience, with a particular emphasis on clinical development and regulatory affairs. She has an extensive track record, having supported the advancement of products through the regulatory process in the United States, Canada, and Europe. Ms. Mancini has held executive roles with several biotech companies, including Sirius Genomics and INEX Pharmaceuticals. While at QLT Inc., she was Vice President of Regulatory Affairs for oncology and ocular diseases, playing a significant role in the development of VISUDYNE® and PHOTOFRIN®.
Eric C. Hsu, PhDSenior Vice President, Preclinical Research and Development
Dr. Hsu brings over 20 years of scientific leadership experience in gene transfer technologies, formulation, and process development. His background includes experience with enGene Inc.AI Analysis | Feedback
The key risks for InMed Pharmaceuticals (INM) are primarily associated with the inherent uncertainties of clinical-stage drug development, its financial stability, and the early nature of its product pipeline.
- Clinical Trial Failure and Regulatory Hurdles: InMed Pharmaceuticals is a clinical-stage company with its lead drug candidates, INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration, currently in preclinical stages. The company targets initiating a Phase 1 clinical trial for INM-901 in 2027, following planned pre-Investigational New Drug (IND) meetings with the FDA in Q3 and Q4 2026 for its programs. The progression of these programs is heavily dependent on regulatory feedback and the successful completion of IND-enabling activities. There is a high risk that these drug candidates may fail to demonstrate efficacy or safety in future clinical trials, or face significant delays or outright rejection by regulatory authorities, which is common in pharmaceutical development.
- Insufficient Capital and Dilution Risk: As of December 31, 2025, InMed Pharmaceuticals reported having $7.0 million in cash, cash equivalents, and short-term investments, a decrease from $11.1 million on June 30, 2025. The company anticipates that its current cash will only be sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. With research and development expenses expected to increase substantially in fiscal year 2026 as preclinical work and IND-enabling studies advance, InMed faces a significant risk of needing to raise additional capital in the near future. This could lead to substantial dilution for existing shareholders, particularly given its small market capitalization, which was reported as $2.69 million in March 2026.
- Dependence on a Narrow and Early-Stage Pipeline: The company's future prospects are almost entirely reliant on the successful development and commercialization of a very limited number of drug candidates, all of which are in very early stages of development. The failure of any single lead candidate, such as INM-901 or INM-089, in preclinical studies or early clinical trials could severely impact the company's viability and its ability to generate future revenue.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for InMed Pharmaceuticals' main products are as follows:
- INM-755 (Epidermolysis Bullosa): The global Epidermolysis Bullosa market size was valued at approximately USD 3.6 billion in 2023 and is projected to reach USD 11 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.40% from 2024-2032. Another estimate indicates the market was USD 3.43 billion in 2025 and is expected to reach USD 3.67 billion in 2026. The market size in the seven major markets (7MM - US, Germany, Spain, Italy, France, UK, and Japan) was approximately USD 1,700 million in 2023.
- INM-088 (Glaucoma): The global glaucoma market size was valued at USD 9.41 billion in 2025 and is projected to reach USD 14.23 billion by 2034, with a CAGR of 4.70% from 2025 to 2034. Another report states the global glaucoma treatment market size was USD 6.6 billion in 2024 and is expected to grow to USD 10.5 billion by 2034.
- INM-405 (Pain): The global pain management market size is estimated at USD 81.92 billion in 2025 and is projected to grow to USD 85.63 billion in 2026, reaching USD 106.86 billion by 2031, with a CAGR of 4.53% over 2026-2031. Another source indicates the pain management market size was valued at USD 73.24 billion in 2023 and is expected to reach USD 108.48 billion by 2032.
AI Analysis | Feedback
InMed Pharmaceuticals (NASDAQ: INM) anticipates several key drivers for its future revenue growth over the next two to three years:
- Strategic Partnerships for INM-755 in Epidermolysis Bullosa: Having completed its Phase 2 clinical trial for INM-755, a cannabinol topical cream for epidermolysis bullosa (EB), and demonstrating positive indications of enhanced anti-itch activity, InMed Pharmaceuticals is actively seeking strategic partnerships to advance this program. Such partnerships, if secured, could generate revenue through upfront payments, milestone payments, and future royalties from commercialization.
- Advancement of INM-901 for Alzheimer's Disease: InMed is prioritizing the advancement of INM-901, a proprietary small molecule drug candidate for Alzheimer's disease. The company plans to engage in a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) in the third quarter of 2026 and aims to initiate Phase 1 clinical trials in 2027. Successful progression through these early clinical development stages is expected to drive future value and potential partnership opportunities.
- Advancement of INM-089 for Age-related Macular Degeneration (AMD): Leveraging its expertise in ocular cannabinoid treatments, InMed is advancing INM-089 for dry age-related macular degeneration. Preclinical research for INM-089 has shown promising results in preserving retinal function. A pre-IND meeting with the FDA is scheduled for the fourth quarter of 2026. This progression is expected to contribute to future revenue growth through potential licensing deals or partnerships.
- Growth and Market Expansion of BayMedica's Commercial Business: InMed's wholly-owned subsidiary, BayMedica, focuses on the manufacturing and distribution of rare cannabinoids for the health and wellness sector. Despite recent revenue fluctuations and market uncertainties, InMed continues to emphasize BayMedica's role in driving revenue growth and market expansion. In fiscal year 2023, BayMedica reported $4.1 million in revenue, a 280% increase over the previous fiscal year, and generated $1.3 million in revenue for the three months ending September 30, 2024, marking a 40% increase year-over-year.
AI Analysis | Feedback
Share Issuance
- In June 2025, InMed announced a private placement for approximately $5 million in gross proceeds through the issuance and sale of common shares and short-term preferred investment options.
- In November 2022, the company completed a private placement of approximately $6 million, issuing common shares and unregistered preferred investment options to institutional investors.
- In December 2024, InMed entered into a Standby Equity Purchase Agreement (SEPA) allowing the sale of up to $10 million of common shares over a 36-month period, providing flexible access to capital.
Inbound Investments
- In June 2025, InMed secured roughly $5 million in gross proceeds from a private placement with a single institutional investor.
- In November 2022, the company received approximately $6 million in gross proceeds from a private placement with two institutional investors.
- In June 2021, InMed raised approximately US$12.0 million through a private placement with an institutional investor.
Outbound Investments
- In November 2021, InMed acquired BayMedica, which provided multiple manufacturing approaches for rare cannabinoids and diversified the company's profile.
- In March 2026, the company decided to wind down and exit BayMedica's commercial operations to focus exclusively on advancing its core drug development programs.
Capital Expenditures
- For the fiscal year ended June 30, 2025, InMed Pharmaceuticals reported property, equipment, and right-of-use assets, net, of $992,199, compared to $1,249,999 for the fiscal year ended June 30, 2024.
- The company expects its cash to be sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.
- Capital expenditures are primarily focused on advancing the pharmaceutical pipeline development, particularly for drug candidates such as INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can InMed Pharmaceuticals Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to INM.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.50 |
| Mkt Cap | 0.1 |
| Rev LTM | 5 |
| Op Inc LTM | -8 |
| FCF LTM | -6 |
| FCF 3Y Avg | -7 |
| CFO LTM | -6 |
| CFO 3Y Avg | -6 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -0.8% |
| Rev Chg 3Y Avg | 22.9% |
| Rev Chg Q | -8.1% |
| QoQ Delta Rev Chg LTM | -1.7% |
| Op Mgn LTM | -93.7% |
| Op Mgn 3Y Avg | -103.0% |
| QoQ Delta Op Mgn LTM | -3.8% |
| CFO/Rev LTM | -73.5% |
| CFO/Rev 3Y Avg | -74.4% |
| FCF/Rev LTM | -82.4% |
| FCF/Rev 3Y Avg | -80.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 4.6 |
| P/EBIT | -2.9 |
| P/E | -3.6 |
| P/CFO | -0.4 |
| Total Yield | -27.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -30.5% |
| D/E | 0.0 |
| Net D/E | -0.9 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.4% |
| 3M Rtn | -6.0% |
| 6M Rtn | -28.1% |
| 12M Rtn | 39.7% |
| 3Y Rtn | -1.4% |
| 1M Excs Rtn | 1.4% |
| 3M Excs Rtn | -0.6% |
| 6M Excs Rtn | -24.7% |
| 12M Excs Rtn | 27.4% |
| 3Y Excs Rtn | -31.0% |
Price Behavior
Price Behavior
| Market Price | $0.66 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/12/2020 | |
| Distance from 52W High | -83.1% | |
| 50 Days | 200 Days | |
| DMA Price | $0.91 | $1.77 |
| DMA Trend | down | down |
| Distance from DMA | -28.2% | -63.0% |
| 3M | 1YR | |
| Volatility | 84.7% | 112.4% |
| Downside Capture | 2.08 | 1.68 |
| Upside Capture | 73.62 | 76.77 |
| Correlation (SPY) | 25.6% | 18.5% |
INM Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.43 | 1.49 | 1.95 | 1.82 | 1.07 | 1.04 |
| Up Beta | -1.08 | 1.08 | 0.11 | 1.20 | 0.71 | 0.45 |
| Down Beta | 5.68 | 3.54 | 2.63 | 2.39 | 0.98 | 2.25 |
| Up Capture | -60% | -77% | 69% | 10% | 49% | 3% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 6 | 14 | 24 | 52 | 107 | 329 |
| Down Capture | 251% | 202% | 304% | 239% | 149% | 111% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 22 | 30 | 61 | 129 | 400 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INM | |
|---|---|---|---|---|
| INM | -72.5% | 113.5% | -0.66 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 7.3% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 18.3% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 3.3% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -1.9% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 6.5% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INM | |
|---|---|---|---|---|
| INM | -79.5% | 146.6% | -0.54 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 8.3% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 14.1% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 3.2% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 3.7% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 8.5% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INM | |
|---|---|---|---|---|
| INM | -53.7% | 143.9% | -0.47 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 8.5% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 14.1% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 3.3% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 4.1% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 8.2% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2020 | 0.9% | -4.7% | -11.3% |
| SUMMARY STATS | |||
| # Positive | 1 | 0 | 0 |
| # Negative | 0 | 1 | 1 |
| Median Positive | 0.9% | ||
| Median Negative | -4.7% | -11.3% | |
| Max Positive | 0.9% | ||
| Max Negative | -4.7% | -11.3% | |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/11/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 09/23/2025 | 10-K |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/30/2024 | 10-K |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 09/29/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/23/2022 | 10-K |
| 03/31/2022 | 05/13/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.